Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.

Reiss, Ulrike M; Schwartz, Jeffrey; Sakamoto, Kathleen M; Puthenveetil, Geetha; Ogawa, Masayo; Bedrosian, Camille L; Ware, Russell E

Reiss, Ulrike M; Schwartz, Jeffrey; Sakamoto, Kathleen M; Puthenveetil, Geetha; Ogawa, Masayo; Bedrosian, Camille L; Ware, Russell E.

Affiliation

Reiss UM; Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Pediatr Blood Cancer ; 61(9): 1544-50, 2014 Sep.

Article in En | MEDLINE | ID: mdl-24777716

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Hemoglobinuria, Paroxysmal/drug therapy; Quality of Life; Adolescent; Antibodies, Monoclonal, Humanized/pharmacokinetics; Child; Female; Follow-Up Studies; Humans; Male; Prognosis; Prospective Studies; Safety; Tissue Distribution

Key words

children; complement inhibition; eculizumab; paroxysmal nocturnal hemoglobinuria; phase I/II

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Antibodies, Monoclonal, Humanized / Hemoglobinuria, Paroxysmal Type of study: Clinical_trials / Observational_studies / Prognostic_studies Aspects: Patient_preference Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2014 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google